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Abstract 
Background: Human endogenous retroviruses (HERVs), the remnants of ancient retroviral infections, constitute 
approximately 8% of human genomic DNA. Since HERV-K Gag expression is induced by HIV-1 Tat in T cells, induced 
HERV-K proteins could affect HIV-1 replication. Indeed, previously we showed that HERV-K Gag and HIV-1 Gag coas-
semble and that this appears to correlate with the effect of HERV-K Gag expression on HIV-1 particle release and its 
infectivity. We further showed that coassembly requires both MA and NC domains, which presumably serve as scaf-
folding for Gag via their abilities to bind membrane and RNA, respectively. Notably, however, despite possessing these 
abilities, MLV Gag failed to coassemble with HIV-1 Gag and did not affect assembly and infectivity of HIV-1 particles. It 
is unclear how the specificity of coassembly is determined.
Results: Here, we showed that coexpression of HERV-K Gag with HIV-1 Gag changed size and morphology of prog-
eny HIV-1 particles and severely diminished infectivity of such progeny viruses. We further compared HERV-K-MLV 
chimeric constructs to identify molecular determinants for coassembly specificity and for inhibition of HIV-1 release 
efficiency and infectivity. We found that the CA N-terminal domain (NTD) of HERV-K Gag is important for the reduc-
tion of the HIV-1 release efficiency, whereas both CA-NTD and major homology region of HERV-K Gag contribute to 
colocalization with HIV-1 Gag. Interestingly, these regions of HERV-K Gag were not required for reduction of progeny 
HIV-1 infectivity.
Conclusions: Our results showed that HERV-K Gag CA is important for reduction of HIV-1 release and infectivity but 
the different regions within CA are involved in the effects on the HIV-1 release and infectivity. Altogether, these find-
ings revealed that HERV-K Gag interferes the HIV-1 replication by two distinct molecular mechanisms.
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Background
Long terminal repeat (LTR)-bounded elements, which 
are called human endogenous retroviruses (HERVs), 
comprise about 8% of the human genome [1–3]. HERVs 
have infected germ lineage cells, and therefore their 
proviruses are transmitted vertically from ancestors to 
progeny in human genomic DNA [4]. During a period 
exceeding a million years, they have acquired numerous 
mutations or deletions and therefore no longer encode 
infectious retrovirus [5]. HERV-K, which is relatively new 
endogenous retrovirus among HERV families, apparently 
contains a set of intact open reading frames [6]. However, 
all known HERV-K proviruses are replication incompe-
tent [7–9]. Two groups reconstructed infectious HERV-K 
sequences by aligning full-length HERV-K proviruses [9, 
10]. The infectious HERV-K clones have become a widely 
used tool for biological research of HERV-K.
Virion assembly of HIV-1 as well as HERV-K occurs 
at the plasma membrane (PM) [9, 11]. HIV-1 Gag con-
sists of four major domains, matrix (MA), capsid (CA), 
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nucleocapsid (NC) and p6 [12]. These domains mediate 
each step of the virion assembly events. The MA domain 
promotes Gag targeting and binding to the PM. The CA 
domain mediates the Gag–Gag interactions for assem-
bly of the immature virion and formation of conical shell 
of the mature viral core. The NC domain binds the viral 
genome through the two zinc finger motifs and facilitates 
Gag multimerization during viral assembly. p6, which 
contains late domain motifs, binds TSG101 and ALIX, 
recruits the ESCRT machinery and facilitates release of 
nascent virus particles from the PM [13–15]. Similar to 
HIV-1 Gag, HERV-K Gag consists of 4 major domains, 
MA, CA, NC and p15 [16, 17]. The N-terminus of the 
MA domain is likely myristoylated and essential for Gag 
binding to the PM [18]. The CA domain contains the 
major homology region (MHR) that is conserved among 
retroviruses [16]. The NC domain encodes two zinc fin-
ger motifs for RNA binding [16, 17]. The late domain in 
p15 is essential for the pinch-off of virus from the PM 
[19]. Unlike the p6 domain of HIV-1 Gag, p15 is located 
between MA and CA in HERV-K Gag. The functions of 
each domain of HERV-K Gag are likely to be similar to 
those of HIV-1 Gag [16–20].
All human cells harbor HERV-K genomes. HERV-K 
is expressed in germ cells and under some pathological 
conditions [21–25]. In HIV-1-infected patients, antibod-
ies and T cell responses against HERV-K are detected 
[26–30]. Furthermore, HERV-K RNA and Gag protein 
are upregulated in plasma samples of HIV-1-infected 
patients [28, 31–36]. It has been also shown that HIV-1 
Tat changes the state of heterochromatin and induces the 
HERV-K expression in somatic cells [37–39]. Thus, it is 
possible that HERV-K Gag exists simultaneously with 
HIV-1 Gag in same host cells. In our previous study, we 
observed that HERV-K Gag of the reconstructed clone 
coassembles with HIV-1 Gag at the PM when overex-
pressed [18]. For the coassembly of HERV-K Gag with 
HIV-1 Gag, membrane binding via MA domains and 
RNA binding via NC domains are essential. Importantly, 
the virus release efficiency and infectivity of HIV-1 were 
substantially reduced when coassembly of HIV-1 Gag 
with HERV-K Gag was observed.
Previously, we showed that HIV-1 Gag coassembles 
with HERV-K Gag but not MLV Gag [18]. However, MLV 
Gag binds the PM and RNA like HERV-K Gag. There-
fore, it is likely that there is an unknown mechanism 
that determines the specificity of interaction between 
HERV-K Gag and HIV-1 Gag. In this study, we deter-
mined the domains responsible for the specific interac-
tion between HERV-K Gag and HIV-1 Gag. We found 
that HERV-K Gag CA MHR promotes specific colocali-
zation with HIV-1 Gag most efficiently, whereas HERV-
K Gag CA N-terminal domain (NTD) is needed for 
HERV-K-Gag-mediated interference of HIV-1 release. 
However, both HERV-K Gag CA-MHR and CA-NTD 
were not required for reduction of HIV-1 infectiv-
ity, which coincided with a change in the size of HIV-1 
particles. Together, these data provide the two distinct 




For expression of HERV-K Gag, pCRVI/HERV-K/Gag, a 
kind gift from P. Bieniasz, was used in this study [9]. This 
plasmid encodes the HERV-KCON Gag sequence following a 
CMV promoter and a sequence corresponding to the HIV-1 
5′ untranslated region (nt 428–785 in pNL4-3), along with 
ORFs encoding HIV-1 Rev, Tat, and Vpu. pCRVI/HERV-
K/Gag-Flag, pCRVI/HERV-K/Gag-Venus, pCRVI/HIV-1/
Gag-Flag, pCRVI/HIV-1/Gag-Venus, pCRVI/HIV-1/Gag-
mRFP, pCRVI/MLV/Gag-Flag, and pCRVI/MLV/Gag-
Venus were described previously [18]. Chimeric HERV-K 
Gag constructs were derived from the pCRVI/HERV-K 
Gag-Flag and pCRVI/MLV Gag-Flag. TSG101-DN was con-
structed in the same design as Tsg-5’ described previously 
[40]. HIV-1/YP(−) was created by PCR mutagenesis and 
contains amino acid substitutions in the ALIX binding motif 
(YP).
Cells
HeLa cells and TZM-bl cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) (Sigma) supple-
mented with 5% FBS (DMEM-10). TZM-bl (also called 
JC.53.bl-13) is a HeLa cell derivative that stably expresses 
large amounts of CD4 and CCR5 [41]. TZM-bl cells that 
harbor Tat-responsive reporter genes for firefly luciferase 
(Luc) and Escherichia coli B-galactosidase were obtained 
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH from Dr. John C. 
Kappes, Dr. Xiaoyun Wu and Tranzyme Inc [42].
p24 ELISA
HeLa cells were cotransfected with pNL4-3 and indi-
cated pCRVI plasmids using lipofectamine 2000 (Invit-
rogen) according to the manufacturer’s instructions. At 
16  h post-transfection, the supernatants were filtered 
through 0.45-μm filters, and virions in the supernatants 
were pelleted down by ultracentrifugation (83,500×g, 
4 °C, 45  min). Gag proteins in the virion lysates were 
quantified by p24 ELISA according to the manufacturer’s 
instruction (MBL).
Virus release assay
HeLa cells were cotransfected with pNL4-3 and indicated 
pCRVI plasmids. At 16 h post-transfection, virions in the 
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supernatants were collected and pelleted down by ultra-
centrifugation (83,500×g, 4 °C, 45 min). Cells and virions 
were lysed with 0.5% TritonX lysis buffer [50 mM Tris–
HCl pH7.5 containing 0.5% TritonX-100, 300 mM NaCl, 
10  mM Iodoacetamide with protease inhibitor cock-
tail (Roche)]. Gag proteins in the cell and virion lysates 
were detected by immunoblotting using HIV-Ig (NIH 
AIDS Research and Preference Reagent Program), mouse 
monoclonal anti-Flag antibody (Wako), mouse monoclo-
nal anti-HERV-K Gag antibody (HERM-1831-5) (Aus-
tral Biologicals) as primary antibodies. HRP-conjugated 
anti-human Ig antibodies (Jackson ImmunoResearch) 
and anti-mouse Ig (Amersham) were used as a second-
ary antibody. Detection using a HRP-conjugated second-
ary antibody was performed using the Chemi-Lumi One 
L (Nacalai tesque).
Rate‑zonal gradient analysis
Rate-zonal gradient analysis was performed as previously 
described [43]. Virions in cell-free supernatants were col-
lected and centrifuged at a low speed (8000×g, 5 min) to 
remove cellular debris. Virions were pelleted by ultracen-
trifugation and re-suspended in 1  ml of RPMI-10. Each 
concentrated sample was layered onto 10–30% sucrose 
and ultracentrifuged (83,500×g, 4 °C, 45 min) in a Beck-
man SW41Ti. Then 1  ml fractions were collected from 
each gradient. Amounts of HIV-1 Gag proteins in each 
fraction were measured by p24 ELISA.
Infectivity analysis of virions in each sucrose fraction
Each sucrose fraction was two-fold diluted with RPMI-
10. For removing sucrose from each fraction, virions in 
each fraction were pelleted down by ultracentrifugation 
and resuspended with RPMI-10. Amounts of virions 
were determined by p24 ELISA.
For analysis of virus infectivity using TZM-bl cells, 
3 × 104 cells were inoculated with virus stocks normal-
ized by the amount of p24 Gag (2 ng of p24 Gag) for 2 h. 
Two days post-infection, Luc activities in TZM-bl cells 
were measured according to the manufacturer’s instruc-
tion (Promega).
Fluorescence microscopy
HeLa cells were plated in 8-well chamber slides (Nunc) 
1 day before transfection at 3.0 × 104 cells/well. At 16 h 
post-transfection, HeLa cells cotransfected with plas-
mids encoding YFP- and mRFP-tagged Gag proteins 
were fixed with 4% paraformaldehyde (Wako) in PBS for 
30 min at room temperature, washed once with PBS, and 
mounted in Fluoromount-G (Dako). The images of 20–50 
fields were recorded using a Zeiss LSM 700 laser-scan-
ning confocal microscopy. Colocalization between YFP- 
and mRFP-tagged Gag was quantified using the ZEN 
software (Zeiss) with which we calculate the Pearson cor-
relation coefficient (R-value). We set the entire cell body 
of each YFP- and mRFP-coexpressing cell as the region 
of interest for this analysis. R = 1 represents perfect co-
localization, and R = 0 represents random distributions 
of fluorescence intensities.
Transmission electron microscopy analysis
HeLa cells were transfected with indicated plasmids. 
Cells were fixed 16  h post-transfection with 2% glu-
taraldehyde in PBS. Cells were analyzed on a Hitachi 
H7600 transmission electron microscope as previously 
described [44].
Results
Coassembly of HERV‑K Gag alters HIV‑1 particle properties
We previously reported that ectopic expression of HERV-
K Gag causes coassembly of HIV-1 Gag and HERV-K 
Gag and reduces relative infectivity of the progeny HIV-1 
virions [18]. It appears likely that coassembly of HERV-
K Gag with HIV-1 Gag would disturb the organization 
of Gag lattice that eventually forms HIV-1 particles. To 
determine whether HERV-K Gag changes the morphol-
ogy of HIV-1 particles, we performed transmission elec-
tron microscopy analyses using HeLa cells transfected 
with plasmids expressing HIV-1 and HERV-K Gag. We 
found that particle sizes were different between HIV-1 
and HERV-K (Fig.  1a, b). HIV-1 particles were slightly 
smaller than HERV-K particles (Fig. 1d). Average sizes of 
HIV-1 and HERV-K particles were 131.6 and 156.1 nm, 
respectively. The production of mostly immature HERV-
K particles as shown in Fig. 1b (particles with no obvious 
electron-dense cores) is likely due to the lack of HERV-
K protease. Unlike HIV-1 particles, HERV-K particles 
appeared to form both single and connected particles of 
doublet or more (Fig. 1b), both of which have been also 
shown in reports published by other groups [9, 21]. In the 
presence of both HIV-1 Gag and HERV-K Gag, particles 
appeared larger than HIV-1 particles produced in the 
absence of HERV-K Gag (Fig. 1a, c). Indeed, the average 
size of particles produced by the cotransfected cells was 
146.1 nm (Fig. 1d). Moreover, mature HIV-1 particles are 
rare in the presence of HERV-K Gag (Fig. 1c). The num-
ber of mature particles was 151 out of 232 in the absence 
of HERV-K Gag, whereas the mature particle num-
ber was only 24 out of 256 in the presence of HERV-K 
Gag (Fig. 1e). The extent of reduction in mature particle 
numbers in cotransfected cultures relative to the cul-
tures transfected with HIV-1 alone was constant in both 
110–120 and 130–140  nm ranges of particle size. Since 
HERV-K Gag produces VLPs with the size typically in the 
latter but not the former range (Fig. 1d), it is unlikely that 
mature HIV-1 particles appeared rare just because HIV-1 
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Fig. 1 Coassembly of HERV-K Gag changes properties of HIV-1 particles. HeLa cells expressing HIV-1 molecular clone (a), HERV-K Gag-FLAG (b), 
or HIV-1 molecular clone and HERV-K Gag-FLAG (c) were analyzed by transmission electron microscopy at 16 h post-transfection. Bars in frame 1, 
200 nm; bars in frame 2 and 3, 100 nm. d, e The sizes of VLPs or mature particles, which are released from transfected cells, were measured using 
images of transmission electron microscopy. Total numbers of VLPs examined are 232, 239, and 256 for cultures expressing HIV-1 alone, HERV-K Gag-
FLAG alone, and HIV-1 and HERV-K Gag-FLAG, respectively
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particles were a minor population compared to HERV-
K particles in the cotransfected cultures (Fig. 1e). These 
results suggest that coassembly of HERV-K Gag increases 
the number of HIV-1 particles with aberrant sizes and/
or a maturation defects, which correlates with the previ-
ously observed reduction in the HIV-1 infectivity.
To validate the observed size difference using a differ-
ent method, we fractionated the different size of particles 
in 10–30% rate-zonal sucrose gradients. In stokes’ law, 
larger particles would precipitate faster than smaller par-
ticles. In these experiments, we observed that the peak 
of HIV-1 Gag p24 appeared in a middle fraction (Frac-
tion #06) (Fig.  2a) that is slightly higher than the peak 
of HERV-K Gag (Fraction #07) (Fig.  2b). These results 
indicate that HERV-K particles are indeed slightly larger 
than HIV-1 particles. When HIV-1 Gag and HERV-K 
Gag were coexpressed, we observed that the peaks of 
both HIV-1 Gag p24 and HERV-K Gag shifted to the 
lower fraction (Fraction #08) than when singly expressed 
(Fig.  2a, b). These results indicate that coassembly of 
HERV-K Gag changes the size or density of HIV-1 viri-
ons. Altogether, the electron microscopy and gradient 
results suggest that HERV-K Gag changes the properties 
of HIV-1 virions via coassembly, which may explain the 
observed reduction in infectivity.
HERV‑K Gag CA‑NTD is required for reduction of HIV‑1 
release
HERV-K Gag coassembles with HIV-1 Gag and reduces 
not only HIV-1 infectivity but also HIV-1 release effi-
ciency [18]. We confirmed this effect in a broad range of 
the ratios for plasmids expressing HERV-K and HIV-1 
and additionally observed that the presence of HERV-K 
pro or pol sequence does not affect the HERV K Gag-
mediated reduction of HIV-1 infectivity or HIV-1 release 
efficiency (Additional file 1: Figure S1A–S1D). The reduc-
tion of HIV-1 release requires both HERV-K Gag MA 
and NC domains [18]. These findings suggested that 
MA-mediated Gag-membrane binding and NC-mediated 
Gag-RNA binding are important for interaction between 
HERV-K Gag and HIV-1 Gag. However, MLV Gag, which 
also binds to membrane via MA and RNA via NC like 
HERV-K Gag, did neither interact with HIV-1 Gag nor 
reduce the HIV-1 release. Therefore, it is likely that there 
is a mechanism that distinguishes HERV-K and MLV 
Gag during coassembly with HIV-1 Gag and inhibition 
of HIV-1 release. To determine regions of HERV-K Gag 
responsible for the specific coassembly with HIV-1 Gag, 
we designed chimeric constructs consisting of HERV-K 
Gag and MLV Gag domains (Fig.  3a). These constructs 
were cotransfected with an HIV-1 molecular clone 
into HeLa cells. Amounts of plasmids for transfection 
were adjusted to render similar expression levels of Gag 
chimeras in HeLa cells, and under this condition virus 
release was compared by immunoblotting (Fig.  3b). In 
another set of experiments, we examined the amounts of 
p24 released into the supernatants of cells cotransfected 
in the same way using p24 ELISA (Fig. 3c). These experi-
ments showed that HIV-1 release was reduced by ectopic 
expression of HERV-K Gag but not by expression of MLV 
Gag as observed previously (Fig.  3b, c). We found that 
Gag chimeras containing HERV-K CA reduced HIV-1 
release efficiency as WT HERV-K Gag. In contrast, MLV 
CA-containing Gag chimeras did not reduce HIV-1 
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Fig. 2 Coassembly with HERV-K Gag changes the size of particles 
containing HIV-1 p24 Gag. HeLa cells were separately transfected or 
cotransfected with the HIV-1 molecular clone pNL4-3 and indicated 
plasmids. For analysis of particles containing single Gag (gray square), 
the supernatants from separately transfected HeLa cells were col-
lected and pooled. For coassembled particles (black square), the 
supernatant of cotransfected HeLa cells was used. These viruses were 
fractionated in rate-zonal gradient analysis. The amounts of HIV-1 Gag 
were measured by ELISA (a), and the amounts of HERV-K Gag were 
measured by immunoblotting using anti-Flag antibody (b). Repre-
sentative data from five independent experiments are shown




























































































































Fig. 3 Coexpression of Gag chimeras containing HERV-K CA reduces HIV-1 release efficiency. a pCRVI/HeHeM, HeMHe, MHeHe, MMHe, MHeM and 
HeMM encode chimeras between HERV-K Gag and MLV Gag. All chimeric Gag constructs are tagged with the Flag epitope. b Cell and viral lysates 
from cotransfected cells were subjected to SDS-PAGE and analyzed by immunoblotting with HIV-Ig or anti-Flag antibody. c HeLa cells were cotrans-
fected with the HIV-1 molecular clone pNL4-3 and indicated plasmids. The amount of p24 in the virus pellet was measured by ELISA. An empty 
vector pCRVI was used as a control. pCRVI/HERV-K Gag-Flag and pCRVI/MLV Gag-Flag express Flag-tagged HERV-K Gag and MLV Gag, respectively. 
Data from three independent experiments are shown as means ± standard deviations
Page 7 of 16Monde et al. Retrovirology  (2017) 14:27 
MA and NC domains (Fig.  3b, c). These results indi-
cate that the CA domain of HERV-K Gag is required for 
reduction of HIV-1 release.
We further analyzed HERV-K CA regions responsible 
for suppression of HIV-1 release using CA-NTD and 
-CTD chimeras (Fig.  4a). A MHR which is conserved 
among retroviruses, is also present at the N-terminal 
part of the HERV-K Gag CA-CTD [16]. Therefore, we 
also constructed CA chimeras that contain the NTD and 
the MHR derived from the same Gag protein (Fig.  4a, 
denoted by “-2”) and compared their effects on HIV-1 
release as done in Fig.  3. HIV-1 release was similarly 
reduced by coexpression of chimeras HeHeMHe-1, 
MHeMM-1, HeHeMHe-2 and MHeMM-2 compared 
to coexpression of WT HERV-K Gag. In contrast, coex-
pression of HeMHeHe-1, MMHeM-1, HeMHeHe-2 
and MMHeM-2 was less efficient in suppressing HIV-1 
release compared to that of WT HERV-K Gag (Fig. 4b, c). 
These results indicate that HERV-K CA-NTD is required 
for efficient reduction of HIV-1 release. Notably, HIV-1 
release was impaired by HeMHeHe-1 but not by HeM-
HeHe-2 (Fig.  4b, c). However, CA-MHR itself did not 
affect the HIV-1 release efficiency (Fig. 4d, e). Consider-
ing these results and the moderate suppression of HIV-1 
release by MMHeM-1, HERV-K CA-MHR in the context 
of HERV-K CA-CTD seems to cause moderate suppres-
sion of HIV-1 release regardless of NTD. Altogether, 
these results suggest that HERV-K CA-NTD is required 
for reduction of HIV-1 release and that the combination 
of HERV-K CA-MHR and -CTD may contribute to, but 
is not essential for, suppression of HIV release by HERV-
K Gag.
HERV‑K Gag reduces the HIV‑1 assembly at the early steps
To investigate the mechanism by which HERV-K Gag 
reduces the HIV-1 release, we used dominant-negative 
TSG101 (TSG101-DN), which inhibits ESCRT-medi-
ated pinching off of HIV-1 particles from the PM [45]. 
We used HIV-1/YP(−) to suppress ESCRT recruitment 
via ALIX so as to specifically examine the TSG101-
dependent HIV-1 release. HERV-K Gag further reduced 
the HIV-1 release about 50% both in the presence and 
absence of TSG101-DN. This result indicates that HERV-
K Gag is likely to inhibit the stage separable from and 
hence earlier than the pinching off of HIV-1 particles 
(Fig. 5).
To examine which HIV-1 assembly step HERV-K 
Gag inhibits, we used HIV-1 mutants EE75/76AA, 
P99A, RS100/102AA, TT107/108AA, TQ110/112AA, 
VK181/182AA, WM184/185AA, LL189/190AA, K158A, 
D197A and P224A. HIV-1 Gag containing mutations 
VK181/182AA, WM184/185AA and LL189/190AA are 
defective in forming CA-CTD dimer [46–52]. Recent 
studies [52] suggest that CA-CTD base mutations K158A, 
D197A and P224A destabilize the first membrane-tar-
geted assembly intermediate, while the CA-CTD dimer 
interface residues (V181, K182, W184, M185, L189, L190) 
are required for continued multimerization of Gag at the 
PM. These and other studies also showed that mutations 
EE75/76AA, P99A [53, 54], RS100/102AA, TT107/108AA 
and TQ110/112AA are defective in the final step of HIV-1 
particle assembly. We found that the release efficiency 
of HIV-1 mutants, EE75/76AA, P99A, RS100/102AA, 
TT107/108AA, TQ110/112AA, D197A, was further 
reduced upon ectopic expression of HERV-K Gag ver-
sus MLV Gag (Fig.  6). However, the release efficiency 
of HIV-1 mutants VK181/182AA, WM184/185AA, 
LL189/190AA, K158A and P224A upon coexpression of 
HERV-K Gag was similar to that observed upon coexpres-
sion of MLV Gag (Fig. 6). These results suggest that intact 
HIV-1 CA-CTD or CA-CTD-mediated dimerization is 
prerequisite for inhibition by HERV-K Gag.
HERV‑K CA‑MHR plays a key role in robust colocalization 
between HERV‑K Gag and HIV‑1 Gag at the plasma 
membrane
To determine whether HERV-K Gag chimeras colocal-
ize with HIV-1 Gag at the PM, HeLa cells were cotrans-
fected with plasmids encoding YFP-tagged Gag chimera 
(or parental HERV-K or MLV Gag-YFP) and mRFP-
tagged HIV-1 Gag. The localization of fluorescent-
protein-tagged Gag proteins was determined using 
confocal microscopy 16  h post-transfection. As shown 
in previous studies, we observed punctate localization 
of HERV-K Gag-YFP at the PM and partial colocaliza-
tion between HERV-K Gag-YFP and HIV-1 Gag-mRFP 
(Figs. 7a, 8a). In contrast, MLV Gag-YFP did not colocal-
ize with HIV-1 Gag-mRFP (Figs. 7a, 8a), as observed in 
previous reports [18, 55]. Therefore, we predicted that 
YFP-tagged constructs of Gag chimeras that efficiently 
inhibit HIV-1 release (e.g., MHeM) would colocalize 
with HIV-1 Gag-mRFP more extensively than those that 
do not (e.g., HeMHe). As expected, MHeHe and MHeM 
Gag-YFP colocalized with HIV-1 Gag-mRFP, whereas 
HeMHe Gag-YFP did not colocalize with HIV-1 Gag-
mRFP (Fig. 7a, b and Additional file 2: Figure S2A). How-
ever, HeHeM Gag-YFP did not colocalize with HIV-1 
Gag-mRFP despite its strong inhibitory effect on HIV-1 
release (Fig.  3). It appears that HeHeM Gag-YFP coex-
pression efficiently increases HIV-1 Gag localization in 
the cytosol and decreases its PM localization (Fig.  7c). 
Therefore, HIV-1 Gag that formed multimers with 
HeHeM Gag might detach from the PM and accumu-
lated in the cytosol. While membrane binding of HERV-
K Gag is necessary for inhibition of HIV-1 release [18], at 
this point we do not rule out the possibility that HeHeM 
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Gag-YFP may be able to suppress HIV-1 assembly with-
out or prior to colocalization with HIV-1 Gag at the PM. 
To further determine the important region in the HERV-
K CA domain for colocalization with HIV-1 Gag, HeLa 
cells were cotransfected with YFP-tagged CA chimeras 
and HIV-1 Gag-mRFP (Fig.  8a, b and Additional file  2: 
Figure S2B). Unexpectedly, all of these Gag-YFP chime-
ras colocalized with HIV-1 Gag-mRFP more efficiently 
than MLV Gag-YFP (Fig. 8a, b and Additional file 2: Fig-
ure S2B). Among them, HeHeMHe-1 and MHeMM-1, 
both of which encode CA-NTD of HERV-K Gag, as well 
as HeMHeHe-2 and MMHeM-2, showed only intermedi-
ate colocalization with HIV-1 Gag. On the other hand, 
HeMHeHe-1, MMHeM-1, HeHeMHe-2 and MHeMM-
2, all of which encode HERV-K CA-MHR, colocalize 
as efficiently with HIV-1 Gag-mRFP as HERV-K Gag 
regardless of the origin of CA-NTD. Furthermore, substi-
tution of CA-MHR alone allowed efficient colocalization 
of MLV Gag with HIV-1 Gag (Fig.  8a, b). These results 
suggest that HERV-K Gag CA-MHR promotes colocali-
zation between HIV-1 Gag and HERV-K Gag; however, 
both HERV-K CA-NTD and the region downstream 
of MHR are capable of mediating partial colocalization 
with HIV-1 Gag. Notably, colocalization efficiency does 
not fully correlate with the efficiency of HIV-1 release 
inhibition. For chimeric Gag proteins encoding HERV-
K CA-NTD, only the partial colocalization appears to be 
enough for the reduction of HIV-1 release.
HERV‑K CA‑NTD and MHR are not required for reduction 
of HIV‑1 infectivity
To test whether the same region of HERV-K Gag is 
responsible for inhibition of HIV-1 release and virion 
infectivity, we compared HeMHeHe-1 and -2 with WT 
HERV-K Gag for the effects on HIV-1 particle properties. 
Upon coexpression of the chimeras, the peak of HIV-1 
Gag p24 in the rate zonal gradient analysis shifted toward 
bottom compared to when HIV-1 is singly expressed 
although the shift was smaller than that observed in the 
presence of WT HERV-K Gag (Fig.  9a). These results 
suggest that HERV-K CA-NTD is not absolutely required 
for changing the property of HIV-1 particles.
To examine the infectivity of HIV-1 particles with the 
larger size, we purified the fractionated viruses from 
sucrose gradients. The purified virus in each fraction was 
normalized by amounts of p24 antigens. TZM-bl cells, 
which encodes Tat-driven luciferase gene, were infected 
with these normalized viruses. The infectivity of HIV-1 
in the fraction #04 was not severely reduced by HERV-
K Gag (Fig.  9b). However, the infectivity of HIV-1 in 
the fractions #07-09, which are likely to be enriched in 
coassembled particles, was drastically reduced (Fig. 9b). 
Chimeric HERV-K Gags encoding MLV Gag CA-NTD 
reduced the infectivity of HIV-1 similarly. These results 
suggest that HERV-K CA-NTD is not necessary for 
inhibition of HIV-1 infectivity (Fig. 9b). In addition, the 
presence of HERV-K CA MHR, which is important for 
extensive colocalization with HIV-1 Gag (Fig.  8), did 
not exacerbate the infectivity defect of HIV-1 virions, 
(See figure on previous page.) 
Fig. 4 Coexpression of Gag chimeras containing HERV-K CA-NTD reduces HIV-1 release efficiency. a pCRVI/HeHeMHe-1, HeMHeHe-1, MHeMM-1, 
MMHeM-1, HeHeMHe-2, HeMHeHe-2, MHeMM-2 and MMHeM-2 encode CA-domain chimeras between HERV-K Gag and MLV Gag. HERV-K MHR 
and MLV MHR are shown in green and blue, respectively. This same color coding is used to indicate constructs containing the different MHRs in the 
subsequent panels in Figs. 4, 8, and 9. b, d Cell and viral lysates from cotransfected cells were subjected to SDS-PAGE and analyzed by immunoblot-
ting with HIV-Ig or anti-Flag antibody. c, e HeLa cells were transfected with pNL4-3 and indicated plasmids. The amount of p24 was measured as 






































Fig. 5 HERV-K Gag reduces release efficiency of HIV-1 at a stage prior 
to particle pinching-off. HeLa cells were cotransfected with HIV-1/
YP(−) and indicated pCMV plasmids and pCRVI plasmids. The amount 
of p24 in the virus pellet was measured by ELISA
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suggesting that HERV-K CA MHR and the high-level 
colocalization dependent on this region are dispensable 
for inhibition of HIV-1 infectivity.
Discussion
In this study, we found that HERV-K Gag CA-NTD 
is important for efficient inhibition of HIV-1 release, 
whereas CA-MHR is required for higher colocalization 
between HIV-1 Gag and HERV-K Gag, and yet both 
CA-NTD and CA-MHR are not essential for inhibition 
of infectivity. These findings suggest that HERV-K Gag 
inhibits HIV-1 release and impairs infectivity of released 
progeny virions in genetically separable mechanisms.
HERV-K Gag consists of 4 major domains, MA, p15, 
CA and NC domains. Previously, we suggested that 
HERV-K Gag coassembles with HIV-1 Gag at the PM in 
a manner dependent on MA-mediated membrane bind-
ing and NC-mediated RNA binding [18]. However, MLV 
Gag, which binds to the PM and RNA just like HERV-K 
Gag, did not colocalize or coassemble with HIV-1 Gag 
and failed to inhibit HIV-1 release. It was unclear how 
HERV-K Gag, but not MLV Gag, targets to the assem-
bly sites of HIV-1 Gag at the PM. In this study, we found 
that HERV-K CA, when replaced with MLV CA, can pro-
mote colocalization of MLV Gag with HIV-1 Gag at the 
PM in most cases (Fig.  7b). Among the tested HERV-K 
CA regions, MHR promotes the colocalization most effi-
ciently (Fig.  8b). Nonetheless, it appears that any of the 
tested HERV-K CA regions is capable of promoting colo-
calization with HIV-1 Gag.
We observed that a single chimera, HeHeM, showed 
minimal correlation of distribution with HIV-1 Gag 
despite containing the entire HERV-K CA. It is possible 
that this chimera suppresses the HIV-1 assembly pro-
cess at the step of membrane binding of Gag multimer. 
We speculate that heteromultimerization between HIV-1 
Gag and HeHeM Gag might destabilize PM binding of 
the Gag multimer at an early step of HIV-1 assembly (see 
below), prevent formation of prominent coassemblies 
at the PM, and thereby reduce colocalization between 
HIV-1 Gag and the chimera. In this regard, it is of note 





































































































Fig. 6 HERV-K Gag reduces release efficiency of HIV-1 through inhibition of an early stage. HIV-1 mutants are defective for the HIV-1 assembly at the 
early stage. HeLa cells were cotransfected with indicated HIV-1 mutants and indicated pCRVI plasmids at 10:1 ratio. Two days later, the amount of 
p24 released into the supernatants was measured by ELISA. Data from three independent experiments are shown as means ± standard deviations. 
P values were determined using a Student’s t test. *P < 0.01; **P < 0.001; ***P < 0.0001; n.s. not significant
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value may underestimate the ability of Gag constructs to 
heteromultimerize with HIV-1 Gag if a large fraction of 
cells display only cytosolic HIV-1 Gag as observed in cul-
tures coexpressing WT HERV-K Gag or chimeras con-
taining the entire HERV-K CA.
Based on TSG101 experiments, coassembly of HERV-
K Gag is likely to take place at the early stage of HIV-1 
Gag assembly (Fig.  5). The Lingappa group reported 
that three classes of HIV-1 CA residues are involved in 
distinct steps of virus assembly [52, 56]. Six residues in 
CA-CTD, VK181/182, WM184/185 and LL189/190, are 
involved in the dimerization of CA-CTD. Three resi-
dues in CA-CTD, K158, D197 and P224, are involved in 
the low order multimerization. Finally, eight residues, 
EE75/76, RS100/102, TT107/108 and TQ110/112 in 
CA-NTD are important for the completion of particle 
formation. In this study, we found that release efficiency 
of 5 HIV-1 mutants, VK181/182AA, WM184/185AA, 




























































































































Fig. 7 Most Gag chimeras containing HERV-K CA colocalize with HIV-1 Gag at the plasma membrane (PM). HeLa cells coexpressing YFP-tagged 
HERV-K Gag, MLV Gag or chimeric Gag (green) and mRFP-tagged HIV-1 Gag (red) proteins were examined using fluorescence microscopy at 16 h 
after cotransfection (a). Images acquired at the mid-section of the cells. b The R strength of correlation between fluorescence intensities of pairs 
of indicated Gag-fluorescent protein chimeras was calculated for cells coexpressing these Gag proteins. Data from 11 to 33 cells are shown as 
means ± standard error of the mean (SEM). P values were determined using a Student’s t test. *P < 0.01; ***P < 0.0001; n.s. not significant. c For the 
analysis of HIV-1 Gag localization patterns, we acquired images of 11–33 cells per condition at the middle and top focal plains. If Gag puncta distrib-
utes over the half of the circumference of a cell, the cell is classified as “PM (High signals)”. If Gag distributes less than the half of the cell circumfer-
ence, the cell is classified as “PM (Low signals)”. If there is no Gag-puncta signal at the plasma membrane and in the cytosol in both top and middle 
focal plains of a cell, the cell is classified as “Cytosol”. If there is Gag puncta in the cytoplasm in the middle focal plain, it is classified as “Intra + PM”. 
Data from 11 to 33 cells are shown
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LL189/190AA, K158A and P224A is not reduced by 
HERV-K Gag (Fig. 6). Therefore, the early assembly steps, 
which require Gag dimerization or low-order multimeri-
zation, are likely to be the target of HERV-K Gag or pre-
requisite for the process inhibited by HERV-K Gag. It is 
unclear why the virus release efficiency of D197A mutant 
was reduced by HERV-K Gag unlike that of K158A or 
P224A mutants. However, we observed that the D197A 
mutant releases 10-fold more p24 than K158A and 
P224A mutants in our experiments (Fig. 6). Therefore, it 
is possible that D197A might impose less severe suppres-
sion than K158A or P224A on the stage susceptible to the 
inhibition by HERV-K. We also do not rule out an alter-
native possibility that VK181/182AA, WM184/185AA, 
LL189/190AA, K158A and P224A may directly or indi-
rectly disrupt the interface for HERV-K Gag.
We observed that coexpression of HERV-K Gag 
reduces the number of HIV-1 particles with mature core 
formation (Fig. 1c, e) although it did not cause accumula-
tion of HIV-1 Pr55 Gag in virions (Fig. 3b). In this regard, 
the effect of HERV-K Gag is reminiscent of the effect of 
bevirimat, a maturation inhibitor, except that the CA-SP1 
fragment was not detected in either cells or viruses unlike 
















































































































Fig. 8 Chimeric Gag constructs containing a part of CA partially colocalize with HIV-1 Gag at the PM. HeLa cells coexpressing YFP-tagged HERV-K 
Gag, MLV Gag or chimeric Gag (green) and mRFP-tagged HIV-1 Gag (red) proteins were examined using fluorescence microscopy at 16 h after 
cotransfection (a). Images acquired at the mid-section of the cells. b The R strength of correlation between fluorescence intensities of pairs of 
indicated Gag-fluorescent protein chimeras was calculated for cells coexpressing these Gag proteins. P values were determined using a Student’s t 
test. *P < 0.01; ***P < 0.0001; n.s. not significant
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morphology of HIV-1 virions produced from cells coex-
pressing HERV-K Gag (frame 2 of Fig. 1c) appears similar 
to that of HIV-1 particles produced by cells treated with 
bevirimat [57–59]. Notably, within HERV-K CA regions, 
both CA-NTD and MHR are not required for impairing 
the infectivity of HIV-1 (Fig.  9b). Therefore, it is pos-
sible that HERV-K Gag impairs HIV-1 core formation 
or stability after the processing of HIV-1 Gag and does 
so by interactions with HIV CA via its CA C-terminal 
region outside of MHR. Further studies focused on the 
morphology and biochemical properties of cores of co-
assembled particles containing HERV-K CA chimeras 
should help establish the relationship between HERV-K 
Gag-induced changes in HIV-1 maturation and impair-
ment of its infectivity.
Previous studies observed that HERV-K expression 
is increased upon HIV-1 infection in T cells [33, 39]. 
Consistent with this, we observed HERV-K induction 
by HIV-1 infection in an in  vitro experiment (data not 
shown). It is tempting to suggest that HERV-K sequences 
have existed in the human genome under several selec-
tion pressures and might have protected the host cells 
from the threat of exogenous viruses as are the case with 
other endogenized viruses. Fv1, which is a remnant of 
mouse endogenous retrovirus Gag, interferes with the 
post-entry process of MLV infection [60–63]. Endog-
enous retroelements Fv4, enJSRV Env and Refrex-1 Env 
prevent the entry of exogenous retroviruses MLV [64], 
JSRV [65] and FeLV-2 [66, 67], respectively, through 
receptor masking. Similar to HERV-K [18], enJSRV 
also blocks the JSRV particle formation via its Gag [65]. 
Recently, Wysocka group reported that HERV-K element 
(Rec), which is expressed in early embryogenesis, appears 
to induce an innate immune response (IFITM1) and pro-
tect the host cells from exogenous viral infection [23]. 
In the current study, we showed that HERV-K Gag can 
suppress the HIV-1 assembly at an early step and alter 
the properties of HIV-1 particles, via distinct molecu-
lar mechanisms. Altogether, endogenous retroviral ele-
ments are likely to have been contributing survival of the 
hosts in the evolutionary time scale via a wide variety of 
mechanisms.
Conclusions
HERV-K is principally expressed in germ cells, but even-
tually silenced through the development process. Inter-
estingly, however, accumulating evidence suggests that 
HERV-K reappears in HIV-1-infected patients. We pre-
viously reported that HERV-K Gag coassembles with 
HIV-1 Gag and interferes with the HIV-1 release. Moreo-
ver, HERV-K Gag reduces the infectivity of HIV-1. How-
ever, the molecular mechanisms by which HERV-K Gag 
interferes with HIV-1 replication remain poorly under-
stood. In this study, we found that HERV-K CA domain 
is important for specific incorporation into HIV-1 virions 
and reduction of HIV-1 release. HERV-K Gag interfered 
with HIV-1 Gag assembly at an early step(s) and changed 
HIV-1 particle properties including core formation and 
infectivity. The effects on HIV-1 release and infectivity 
were genetically separable.
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Fig. 9 HERV-K CA-NTD and MHR are not required for reduction of 
HIV-1 infectivity. HeLa cells were cotransfected with pNL4-3 and indi-
cated plasmids. a Virus in the supernatant from cotransfected HeLa 
cells were collected and fractionated in rate-zonal gradient analysis. 
The amount of HIV-1 Gag were measured by ELISA. b Virus stocks 
were prepared from each fraction after rate-zonal gradient analysis. 
The viruses were purified and normalized by p24 ELISA. TZM-bl cells, 
which harbor an HIV-1 LTR-driven luciferase-reporter gene, were 
infected with the purified viruses. At 2 days post-infection, luciferase 
activities were measured by luminometor. Data from three independ-
ent experiments are shown as means ± standard deviations. P values 
were determined using a Student’s t test. *P < 0.01; **P < 0.001; 
***P < 0.0001; n.s. not significant
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Additional files
Additional file 1: Fig. S1. Coexpression of HERV-K GagPro reduces 
HIV-1 release efficiency and infectivity of released particles. HeLa cells 
were cotransfected with HIV-1 pNL4-3 and indicated plasmids encod-
ing non-Flag-tagged Gag at different ratios (A) and at 10:1 ratio (C). The 
amount of p24 was measured as described in Fig. 3c. P values, compared 
with HERV-K Gag, were determined using a Student’s t test. *, P < 0.01; **, 
P < 0.001; ***, P < 0.0001; n.s., not significant. (B) Cell and viral lysates from 
cotransfected cells were subjected to SDS-PAGE and analyzed by immu-
noblotting with HIV-Ig or anti-HERV-K Gag antibody. (D) The viruses were 
recovered from supernatants by ultracentrifugation and normalized by 
p24 ELISA. TZM-bl cells were infected with the recovered viruses. At 2 days 
post-infection, luciferase activities were measured by luminometor. Data 
from three independent experiments are shown as means ± standard 
deviations. P values were determined using a Student’s t test. *, P < 0.01; 
**, P < 0.001; ***, P < 0.0001; n.s., not significant.
Additional file 2: Fig. S2. Chimeric Gag constructs containing a part of 
HERV-K CA colocalize at least partially with HIV-1 Gag at the PM. HeLa cells 
coexpressing YFP-tagged chimeric Gag (green) and mRFP-tagged HIV-1 
Gag (red) proteins were examined using fluorescence microscopy at 16 h 
after cotransfection (A and B). Images were acquired at the mid-section 
of the cells.
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